En español | An advisory panel to the U.S. Food and Drug Administration (FDA) today cast a contentious vote to allow blockbuster diabetes drug Avandia to remain on the market. But the vote was split, and overwhelmingly negative in its judgment about Avandia’s risks, with 12 voting to withdraw the drug from the market altogether, 10 voting for it to be sold only with additional warnings and use restrictions, seven calling for some added warnings, and only three voting for no changes. One panel member abstained. … Back to Article
Join AARP
Join for Just $16 A Year
- Discounts on travel and everyday savings
- Subscription to AARP The Magazine
- Free membership for your spouse or partner
Tell Us WhatYou Think
Please leave your comment below.
You must be signed in to comment.
Sign In | Register